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Rationale: Portopulmonary hypertension (PPHTN) occurs in 6% of
liver transplant candidates. The pathogenesis of this complication of
portal hypertension is poorly understood.
Objectives: To identify genetic risk factors for PPHTN in patients with
advanced liver disease.
Methods: We performed a multicenter case-control study of patients
with portal hypertension. Cases had a mean pulmonary artery pressure
.25 mm Hg, pulmonary vascular resistance .240 dyness21cm25,
and pulmonary capillary wedge pressure <15 mm Hg. Controls had
a right ventricular systolic pressure , 40 mm Hg (if estimated) and
normal right-sided cardiac morphology by transthoracic echocardi-
ography. We genotyped 1,079 common single nucleotide polymor-
phisms (SNPs) in 93 candidate genes in each patient.
Measurements and Main Results: The study sample included 31 cases
and 104 controls. Twenty-nine SNPs in 15 candidate genes were
associated with the risk of PPHTN (P , 0.05). Multiple SNPs in the
genes coding for estrogen receptor 1, aromatase, phosphodiester-
ase 5, angiopoietin 1, and calcium binding protein A4 were associ-
ated with the risk of PPHTN. The biological relevance of one of the
aromatase SNPs was supported by an association with plasma
estradiol levels.
Conclusions: Genetic variation in estrogen signaling and cell growth
regulators is associated with the risk of PPHTN. These biologic
pathways may elucidate the mechanism for the development of
PPHTN in certain patients with severe liver disease.
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Pulmonary arterial hypertension (PAH) is characterized by
elevated pulmonary artery pressure and pulmonary vascular re-
sistance, right heart failure, exercise limitation, and an increased
risk of death. Histopathologic examination reveals intimal pro-
liferation, medial hypertrophy, and adventitial fibrosis in the
small muscular pulmonary arteries. Plexiform lesions and in situ
thrombosis are also seen. Most commonly idiopathic, PAH may
also be associated with portal hypertension, termed portopulmo-
nary hypertension (PPHTN). McDonnell and colleagues showed
a prevalence of histopathologic changes of PAH of 0.61% in
autopsies of patients with cirrhosis, and PPHTN was the third
most common form of PAH in a population-based epidemiologic
study in France (1, 2). Recent cohort studies showed that the
prevalence of PPHTN in patients presenting for liver transplant
evaluation is between 5 and 6% (3–5). Patients with PPHTN have
an increased risk of death, even with specific PAH treatment (4,
6–8). In many cases, PPHTN greatly complicates or precludes
liver transplantation, significantly affecting the course of hepatic
failure in these patients (6,9,10).
The etiology of PAH in patients with portal hypertension
(characterized by systemic vasodilatation) is unclear. We have
shown that female sex and type of liver disease are associated
with the risk of PPHTN (11). Although germline mutations in the
gene that codes for bone morphogenetic protein receptor type II
(BMPR2) have been associated with idiopathic and familial
forms of PAH, they have not been found in patients with PPHTN
(12). Genetic variation in the serotonin transporter (SERT) has
been associated with the risk of PAH in some studies (13) but not
in others (14, 15). We did not find an association between genetic
variation at SERT loci and the risk of PPHTN (16).
We therefore hypothesized that variation in genes other than
BMPR2 and SERT contribute to the risk of developing PPHTN.
We performed a high-throughput candidate gene study in an
attempt to identify common genetic variation associated with the
risk of PPHTN in a group of patients undergoing liver trans-
plantation evaluation. This work has been previously published
in abstract form (17).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
It is believed that inherited factors contribute to the devel-
opment of certain forms of pulmonary arterial hyperten-
sion, such as that associated with portal hypertension.
What This Study Adds to the Field
Genetic polymorphisms in estrogen and other pathways
are associated with the risk of portopulmonary hyperten-
sion in patients with advanced liver disease.
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METHODS
Study Cohort and Study Sample
The Pulmonary Vascular Complications of Liver Disease (PVCLD)
Study enrolled a cohort of 536 patients evaluated for liver trans-
plantation or pulmonary hypertension at seven centers in the United
States between 2003 and 2006. The only inclusion criterion was the
presence of chronic portal hypertension with or without intrinsic liver
disease. We excluded patients with evidence of active infection, recent
(,2 wk) gastrointestinal bleeding, or who had undergone liver or lung
transplantation. The institutional review boards at each of the partici-
pating centers approved this study, and informed consent was obtained.
We performed a case-control study. The study sample included
newly referred patients who were evaluated with transthoracic echo-
cardiography (routinely performed for pretransplant evaluation) dur-
ing the study period. ‘‘Prevalent’’ patients who met the case definition
(see below) were also included. We excluded patients with pulmonary
function testing showing a significant obstructive or restrictive ventila-
tory defect (see online supplement). We also excluded patients with
HIV infection or the presence of more than moderate aortic or mitral
valvular disease or significant left ventricular dysfunction by trans-
thoracic echocardiography.
Case and Control Definitions
Cases with PPHTN met the following criteria at initial evaluation: (1)
mean pulmonary artery pressure . 25 mm Hg, pulmonary capillary
wedge pressure (or left ventricular end-diastolic pressure) < 15 mm Hg,
and pulmonary vascular resistance .240 dyness21cm25 measured by
right heart catheterization; and (2) no other etiology for pulmonary
hypertension. Controls met the following echocardiographic criteria at
entry into the cohort: (1) right ventricular systolic pressure , 40 mm Hg
(if estimable), and (2) absence of right atrial or ventricular dilation,
hypertrophy, or dysfunction. Prevalent cases who had previously un-
dergone evaluation and were subsequently being treated were also
included.
Clinical Variables and Blood Sampling
Data were collected from subjects and the medical record. The Model
for End-stage Liver Disease (MELD) score was calculated (18).
Phlebotomy was performed and blood was collected into EDTA-
containing tubes. Plasma and buffy coat layers were stored at 2808C.
Candidate Genes and Single Nucleotide
Polymorphism Selection
Ninety-three genes affecting vascular function were selected by the
investigators (Table 1). For this study, 1,079 single nucleotide poly-
morphisms (SNPs) in the 93 candidate genes were genotyped (see Table
E1 in the online supplement). We genotyped an additional set of
60 SNPs (null loci) from a validated list of Ancestry Informative Markers
(19) to detect potential population stratification. (See online supplement
for details of gene and SNP selection.)
Genotyping
Genomic DNA was isolated from peripheral leukocytes using standard
procedures (Gentra Puregene; Qiagen, Valencia, CA). SNP genotyping
was performed using the GoldenGate Assay (Illumina, Inc., San Diego,
CA).
Statistical Analysis
Continuous data were summarized using mean 6 standard deviation or
median (interquartile range), as appropriate. Categorical variables were
summarized using n (%). Unpaired Student t tests, Wilcoxon rank sum
tests, chi-square tests, and Fisher exact tests were used, as appropriate.
Hardy-Weinberg equilibrium (HWE) was assessed for genetic alleles
using Fisher exact tests in controls. The association of genotype with
case/control status was assessed using additive models in multivariate
logistic regression and expressed with odds ratios (ORs). We adjusted
for sex and autoimmune liver disease (previously associated with case
status [11]) in the final multivariate logistic regression models. Because
the main goal of this study was hypothesis generation, adjustment for
multiple comparisons was not performed. Single locus association
analyses were performed using SAS/STAT (SAS Institute, Cary, NC).
For genes in which more than one SNP was associated with PPHTN,
we determined haplotype structure and pairwise linkage disequilibrium
between SNPs using Haploview 4.0 (20). The presence or absence of
population stratification was assessed by comparing allele frequencies of
the 60 null loci between cases and controls using chi-square tests (21).
Sensitivity analyses assessed the potential impact of racial differences or
cryptic subpopulations. P , 0.05 was considered significant for all
analyses.
There was 80% power to detect odds ratios of >2.4 to 4.0 (or <0.25
to 0.42), depending on the minor allele frequency of the SNP (range,
0.45–0.05). Power analysis was performed using QUANTO 1.2 (22).
RESULTS
There were 31 cases and 104 controls. The mean age of the
subjects was 52 6 10 years, and 60 (44%) were female. One
hundred and twenty-one (90%) were white and seven (5%) were
black. Sixteen (13%) of the white subjects were of Hispanic
ethnicity (12% of the study sample). Subjects with PPHTN had
a mean right atrial pressure of 10 6 6 mm Hg (n 5 30), a mean
pulmonary artery pressure of 50 6 9 mm Hg, and pulmonary
capillary wedge pressure (or left-ventricular end-diastolic pres-
sure) of 10 6 4 mm Hg. The cardiac output was 5.5 6 1.8 L/min,
the cardiac index was 2.9 6 0.9 L/min/m2, and the pulmonary
vascular resistance was 672 6 374 dyness21cm25.
Bivariate Analyses
Age, race, and severity of liver disease were similar between the
groups (Table 2). Female sex and autoimmune hepatitis were
associated with an increased risk for PPHTN, as previously
reported in this population (11). One case and one control had
a-1 antitrypsin deficiency, one control had biliary atresia, one
case had sarcoid, and one case had portal vein thrombosis.
Genetic Analyses
Nine hundred and ninety-three (of the 1,079) SNPs conformed to
HWE in controls (P . 0.05) and were included in the analysis.
Twenty-nine SNPs in 15 genes were significantly associated with
PPHTN after adjustment for sex and liver disease etiology
(autoimmune hepatitis) (Table 3). In the gene coding for es-
trogen receptor 1 (ESR1), 7 of 36 SNPs were associated with
either a significantly decreased (OR 5 0.39–0.18) or increased
(OR 5 2.56–2.70) risk of PPHTN. The five protective SNPs
included four intronic and one synonymous Exon 4 SNP
(rs1801132, P324P). Pairwise linkage disequilibrium analyses
demonstrated that these five loci represented a single haplotype
block (D9 5 0.71–0.84) (Table E2 and Figure E1). Distal to these
protective loci, two SNPs (rs7757956 and rs3020368, D9 5 0.89)
were associated with an increased risk of PPHTN. Two promoter
SNPs in the gene coding for aromatase (CYP19A1), the rate-
limiting enzyme in the conversion of the androgens testosterone
and androstenedione to estradiol, were associated with an in-
creased risk of PPHTN (Tables 3 and E2, Figure E2).
Four of nine SNPs genotyped in phosphodiesterase 5
(PDE5A) were in tight linkage disequilibrium (r2 5 0.95–1.00)
(Table E2) and all were associated with an increased risk of
PPHTN (all OR 5 2.11; 95%CI, 1.05–4.22; P 5 0.03) (Table 3).
Two tightly linked SMAD3 intron 1 SNPs (rs4776881 and
rs12324036, r2 . 0.97) were associated with a decreased risk of
PPHTN (both OR 5 0.50; 95%CI, 0.26–0.95; P 5 0.035).
Two SNPs in each of three genes—calcium binding protein A4
(S100A4), angiopoietin 1 (ANGPT1), and retinoic acid receptor,
b (RARB)—were associated with case status and were not in
linkage disequilibrium (Tables 3 and E2, Figure E3). Of note,
polymorphisms in BMPR2 or genes coding for bone morphoge-
netic protein receptor Type Ia (BMPR1A), activin A receptor
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TABLE 1. CANDIDATE GENES (GENE ONTOLOGY ANNOTATION)




Angiotensin I converting enzyme (ACE) NM_152831 17q23 15
Elastin (ELN) NM_000501 7q11 5
Endothelin 1 (EDN1) NM_001955 6p24 7
Endothelin converting enzyme 1 (ECE1) NM_001397 1p36 10
Endothelin receptor, nonselective type (EDNRB) NM_000115 13q22 13
Endothelin receptor, type A (EDNRA) NM_001957 4q31 11
Heme oxygenase 1 (HMOX1) NM_002133 22q13 8
Natriuretic peptide precursor A (NPPA) NM_006172 1p36 13*
Natriuretic peptide precursor B (NPPB) NM_002521 1p36 13*
Nitric oxide synthase 2 (NOS2A) NM_000625 17q11 15
Phosphodiesterase 5 (PDE5A) NM_001083 4q26 9
Potassium channel, voltage-gated, shaker, member 5 (KCNA5) NM_002234 12p13 9
Rho-associated protein kinase 2 (ROCK2) NM_004850 2p24 15




Activin A receptor, type II-like kinase (ACVRL1) NM_000020 12q11 6
Apolipoprotein E (APOE) NM_000041 19q13 4
BCL2-associated X protein (BAX) NM_138764 19q13 6
Bone morphogenetic protein receptor type 1a (BMPR1A) NM_004329 10q22 20
Bone morphogenetic protein receptor type 2 (BMPR2) NM_001204 2q33 12
Caveolin 1 (CAV1) NM_001753 7q31 20*
Caveolin 2 (CAV2) NM_001233 7q31 20*
Caveolin 3 (CAV3) NM_033337 3p25 19
CD14 molecule (CD14) NM_000591 5q22 3
Cyclin-dependent kinase inhibitor 2A (CDKN2A) NM_000077 9p21 13
Growth differentiation factor 2 (GDF2) NM_016204 10q11 5
Homolog of Drosophila mothers against dpp 3 (SMAD3) NM_005902 15q21 34
Homolog of Drosophila mothers against dpp 4 (SMAD4) NM_005359 18q21 5
Nitric oxide synthase 3 (NOS3) NM_000603 7q36 10
Nuclear factor kappa B p100 subunit (NFKB2) NM_001077493 10q24 5
Nuclear factor kappa B p105 subunit (NFKB1) NM_003998 4q23 13
Nuclear factor kappa B p65 subunit (RELA) NM_021975 11q13 4
Prostaglandin I2 synthase (PTGIS) NM_000961 20q13 13
Protein kinase C, alpha (PRKCA) NM_002737 17q22 33
Protein kinase C, beta 1 (PRKCB1) NM_002738 16p11 13
Protein kinase C, gamma (PRKCG) NM_002739 19q13 5
Transforming growth factor, Beta-1 (TGFB1) NM_000660 19q13 5
V-AKT murine thymoma viral oncogene homolog 1 (AKT1) NM_005163 14q32 7
Blood vessel growth and
development
GO:0001568
Angiopoietin 1 (ANGPT1) NM_001146 8q22 37
Calcium-binding protein A4 (S100A4) NM_019554 1q21 6
Endoglin (ENG) NM_000118 9q34 15
Hypoxia-inducible factor 1, alpha subunit (HIF1A) NM_001530 14q21 8
Plasminogen (PLG) NM_000301 6q26 21
Runt-related transcription factor 1 (RUNX1) NM_001754 21q22 58
Thrombospondin-1 (THBS1) NM_003246 15q15 5
Tyrosine kinase with Ig and EGF factor homology domains (TIE1) NM_005424 1p34 8
Vascular endothelial growth factor (VEGF) NM_00125366 6p12 7
Inflammation
GO:0006954
Complement component 4A (C4A) NM_007293 6p21 4
C-reactive protein (CRP) NM_000567 1q21 8
Cytochrome b-245, NADPH oxidase 2, NOX2 (CYBB) NM_000397 Xp21 6
Lipopolysaccharide binding protein (LBP) NM_004139 20q11 7
Tumor necrosis factor (TNF) NM_000594 6p21 5
Oxidation reduction
GO:0006979
Dual oxidase 1 (DUOX1) NM_017434 15q15 15*
Dual oxidase 2 (DUOX2) NM_014080 15q15 15*
NADPH oxidase 1 (NOX1) NM_007052 Xq22 7
NADPH oxidase 4 (NOX4) NM_016931 11q14 19
Superoxide dismutase 1, soluble (SOD1) NM_000454 21q22 3
Superoxide dismutase 2, mitochondrial (SOD2) NM_00636 6q25 3
Xanthine dehydrogenase (XDH) NM_00379 2p23 24
Tissue development
GO:0009888
Homolog of Drosophila mothers against dpp 2 (SMAD2) NM_005901 18q21 10
Ikaros (IKZF1) NM_006060 7p12 7
Peroxisome proliferator activated receptor, gamma (PPARG) NM_005037 3p25 13




Aromatase (CYP19A1) NM_000103 15q21 24
Estrogen receptor 1 (ESR1) NM_000125 6q25 36
Estrogen receptor 2 (ESR2) NM_001437 14q24 14
Farnesoid X receptor (NR1H4) NM_005123 12q 7
Pregnane X receptor (NR1I2) NM_003889 3q13 13
Sex hormone binding globulin (SHBG) NM_001040 17p13 6
Small heterodimer partner (NR0B2) NM_021969 1p36 5
(Continued)
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type II-like 1 (ACVRL1), or endoglin (ENG) were not associ-
ated with PPHTN.
There were no significant differences in allele frequencies of
the 60 null alleles between cases and controls (all P . 0.05),
lessening the chance of population stratification. We assessed
for potential confounding by liver disease etiology (other than
autoimmune hepatitis). Eight SNPs associated with PPHTN
were also independently associated with various liver disease
etiologies; in all cases, adjustment for liver disease etiology
resulted in either no significant change or strengthening of the
association between the SNP and case status (Table E3).
There were no significant differences in the results from the
main analyses and results of analyses performed in females only
(n 5 60), self-identified whites (n 5 121), and subjects with white
genetic ancestry (n 5 124) (data not shown), indicating that
neither sex nor race (nor genetic ancestry-based) differences
accounted for our results.
Plasma Estradiol
Estradiol levels were measured in 28 cases and 98 controls with
available plasma (see online supplement for assay details).
Estradiol levels increased in a dose-dependent fashion with the
A allele of the aromatase rs7175922 SNP (the allele associated
with an increased risk of PPHTN), even after adjustment for sex
(Figure 1). Estradiol levels were not associated with genotypes of
the other aromatase SNP associated with case status (data not
shown).
DISCUSSION
This is the first study to document genetic risk factors for
PPHTN. Using a high-throughput candidate gene approach, we
found SNPs in a variety of genes that were associated with the
development of PAH in patients with advanced liver disease.
Pathways with multiple gene ‘‘hits’’ included estrogen signaling,
cellular growth/apoptosis, and oxidative stress. Other SNPs
associated with case status included those in genes coding for
recombination signal-binding protein 1 for J-kappa (RBPSUH),
inducible nitric oxide synthase (NOS2A), and plasminogen
activator inhibitor-1 (SERPINE1 or PAI-1). A number of the
genes and signaling pathways found here have also been impli-
cated in human or experimental PAH, supporting the concept
that there may be shared pathogenetic mechanisms. In addition,
several novel associations have been shown that may provide
important mechanistic and therapeutic insights.
The role of estrogen signaling and increased estradiol levels in
the pathogenesis of PAH and PPHTN has not been defined.
PPHTN (like idiopathic and familial PAH) affects females more
commonly than males (11), an association that may be related to
a high estrogen state. However, estrogen has traditionally been
TABLE 1. (CONTINUED)
Pathway Gene RefSeq Chr SNPs
Extracellular matrix structure and regulation
GO:0043062
GO:0006508
Collagen, type XVIII, alpha-1 (COL18A1) NM_130445 21q22 29
Elastase 1 (ELA1) NM_001971 12q13 8
Elastase 2 (ELA2) NM_001972 19p13 4
Matrix metalloproteinase 2 (MMP2) NM_004530 16q13 11
Matrix metalloproteinase 3 (MMP3) NM_002422 11q23 6
Matrix metalloproteinase 9 (MMP9) NM_004994 20q11 6
Proteinase inhibitor 3; elafin (PI3) NM_002638 20q12 4
Tenascin C (TNC) NM_002160 9q33 16
Coagulation
GO:0050817
Plasminogen activator inhibitor 1 (SERPINE1) NM_000602 7q21 9
Thrombomodulin (THBD) NM_000361 20p11 4
Thromboplastin (HEMB) NM_000133 Xq27 11




Serotonin 2B receptor (HTR2B) NM_000867 2q36 8
Tryptophan hydroxylase 1 (TPH1) NM_004179 11p15 8
Tryptophan hydroxylase 2 (TPH2) NM_173353 12q21 16
Na/bile acid transporter
GO:0008508
Solute carrier family 10, member 1 (SLC10A1) NM_003049.1 14q24 5
Solute carrier family 10, member 2 (SLC10A2) NM_000452.1 13q33 12
Metabolism
GO:0008152
5,10-methylenetetrahydrofolate reductase (MTHFR) NM_005957 1p36 7
Betaine-homocysteine methyltransferase (BHMT) NM_001713 5q13 4
Cystathionine-beta-synthase (CBS) NM_000071 21q22 6
Peroxisome proliferator activated receptor, alpha (PPARA) NM_005036 22q12 9
Retinoic acid signaling
GO:0048384
Retinoic acid receptor, alpha (RARA) NM_000964 17q21 4
Retinoic acid receptor, beta (RARB) NM_016152 3p24 29
Retinoic acid receptor, gamma (RARG) NM_000966 12q13 6
Definition of abbreviations: Chr 5 chromosome; RefSeq 5 Reference Sequence; SNP 5 single-nucleotide polymorphism.
* Indicates adjacent genes that were defined by a single genomic region and tagging SNPs. Thus the number of SNPs indicated refers to the total number of SNPs
assayed in the region containing both genes.
TABLE 2. DEMOGRAPHIC AND CLINICAL DATA FOR
CASES AND CONTROLS
Variable Cases (N 5 31) Controls (N 5 104) P Value
Age, years 54 6 10 52 6 10 0.41
Female sex 20 (65%) 40 (39%) 0.01
Race 0.37
White 29 (94%) 92 (88%)
Black 0 7 (7%)
Other 2 (6%) 5 (5%)
Etiology of portal
hypertension
Alcohol 14 (45%) 45 (43%) 0.85
Hepatitis C 6 (19%) 51 (49%) 0.003
Autoimmune hepatitis 7 (23%) 4 (4%) 0.003
Nonalcoholic fatty
liver disease
1 (3%) 8 (75%) 0.68
Hepatitis B 1 (3%) 6 (6%) 1.0
Primary sclerosing
cholangitis
1 (3%) 9 (9%) 0.45
Primary biliary cirrhosis 3 (10%) 3 (3%) 0.13
Cryptogenic 2 (6%) 8 (8%) 1.0
Model for End-stage
Liver Disease score
12 6 4 (N 5 29) 12 6 5 (N 5 103) 0.77
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believed to play a protective role in the systemic and pulmonary
vasculature, modulating proliferative and vasoactive signaling by
direct and receptor-mediated mechanisms (23, 24). In animal
models of pulmonary hypertension, estrogen increases nitric
oxide and prostacyclin production and decreases endothelin-1
(25–27), resulting in beneficial vascular effects. Such data are
seemingly difficult to reconcile with studies showing adverse car-
diovascular effects of estrogen. For instance, the Women’s
Health Initiative revealed that (despite many observational
studies suggesting otherwise) hormone replacement therapy
actually increased the risk for adverse cardiovascular events (28).
These apparent paradoxes may be explained by the complex-
ity of the influence of estrogen on vascular homeostasis, resulting
from variable expression of estrogen receptors 1 and 2 (a and b),
cell and tissue specificity, and the influential balance between
estrogen and other steroid hormones, such as testosterone and
progesterone (29–31). We found that genetic variation in both
the estrogen receptor 1 and aromatase (the rate-limiting enzyme
in the conversion of androgens to estrogens) was associated with
the risk of PPHTN, independent of sex. The two aromatase SNPs
(rs1902584 and rs7175922) are located in the 93-kb region
upstream (59) of exon 2, where numerous tissue-specific pro-
moters reside and thus could differentially influence aromatase
expression in tissues (32). Furthermore, the association between
the high-risk aromatase allele (rs7175922) and increased estra-
diol levels supports a functional effect of this SNP. Together,
these findings strongly implicate estrogen signaling in the path-
ogenesis of PPHTN and define specific putative genetic factors
that may contribute.
Several of the genes identified in our study participate in the
regulation of cellular growth and apoptosis and have been im-
plicated in human PAH and/or animal models of PAH. For
example, we found that variation in PDE5A, which codes for
a key enzyme in cyclic guanine monophosphate (cGMP) me-
tabolism, was associated with PPHTN. Phosphodiesterase 5
inhibitors, such as sildenafil, potentiate the antiproliferative and
vasodilatory effects of cGMP and improve hemodynamic
features in PPHTN and other forms of PAH (33–35). Our
TABLE 3. ADDITIVE MULTIVARIATE LOGISTIC REGRESSION MODELS FOR SINGLE NUCLEOTIDE POLYMORPHISMS AND THE RISK OF




Chr Gene Identification Location Risk Allele Cases Controls OR (95% CI) P Value
6 Estrogen receptor 1 (ESR1) rs1913474 Intron 3 A 0.13 0.26 0.33 (0.13–0.85) 0.022
rs1801132 P324P C 0.13 0.27 0.39 (0.12–0.76) 0.011
rs3020317 Intron 4 G 0.13 0.26 0.18 (0.06–0.55) 0.003
rs985694 Intron 4 A 0.11 0.23 0.19 (0.05–0.67) 0.010
rs932477 Intron 4 A 0.07 0.16 0.25 (0.08–0.87) 0.030
rs7757956 Intron 4 A 0.24 0.15 2.70 (1.19–5.88) 0.017
rs3020368 Intron 5 A 0.19 0.12 2.56 (1.09–5.88) 0.031
15 Aromatase (CYP19A1) rs7175922 59 A 0.26 0.13 2.17 (1.00–4.55) 0.050
rs1902584 Intron 1 A 0.15 0.04 3.85 (1.33–11.1) 0.014
4 Phosphodiesterase 5 (PDE5A) rs11731756 Intron 7 C 0.39 0.24 2.11 (1.05–4.22) 0.036
rs10034450 Intron 11 G 0.39 0.24 2.11 (1.05–4.22) 0.036
rs1155576 Intron 11 C 0.40 0.25 2.11 (1.06–4.20) 0.033
rs3775843 Intron 16 G 0.39 0.24 2.11 (1.05–4.23) 0.036
8 Angiopoietin 1 (ANGPT1) rs4324901 Intron 1 A 0.26 0.38 0.48 (0.24–0.97) 0.041
rs4268102 Intron 6 C 0.34 0.19 2.30 (1.16–4.56) 0.017
1 Calcium binding protein A4 (S100A4) rs743687 39utr G 0.18 0.07 3.82 (1.53–9.53) 0.004
rs1810765 39utr G 0.19 0.11 2.38 (1.09–5.20) 0.030
3 Retinoic acid receptor, beta (RARB) rs871963 Intron 2 T 0.63 0.46 1.92 (1.05–3.54) 0.035
rs1153584 Intron 3 A 0.35 0.49 0.44 (0.23–0.88) 0.019
7 Caveolin 1 (CAV1) rs926198 Intron 2 G 0.23 0.38 0.40 (0.19–0.84) 0.016
15 Homolog of Drosophila mothers against dpp 3 (Smad3) rs12324036 Intron 1 A 0.34 0.48 0.50 (0.26–0.95) 0.035
rs4776881 Intron 1 G 0.34 0.48 0.49 (0.26–0.95) 0.035
21 Runt-related transcription factor 1 (RUNX1) rs2294163 Intron 1 A 0.29 0.17 1.96 (1.00–3.85) 0.049
4 Recombining binding protein 1 for J-kappa (RBPSUH) rs2077777 Intron 2 G 0.11 0.05 3.47 (1.15–10.45) 0.027
2 Xanthine dehydrogenase (XDH) rs1896846 Intron 24 C 0.39 0.23 1.96 (1.06–3.70) 0.031
6 Superoxide dismutase 2 (SOD2) rs5746136 39utr A 0.37 0.23 2.00 (1.02–4.00) 0.043
11 NADPH oxidase 4 (NOX4) rs3017887 59utr A 0.05 0.14 3.88 (1.05–14.29) 0.042
7 Plasminogen activator inhibitor 1 (SERPINE1) rs2227714 39utr A 0.06 0.02 7.14 (1.47–33.33) 0.014
17 Nitric oxide synthase 2A (NOS2A) rs1137933 D384D A 0.13 0.28 0.39 (0.17–0.91) 0.030
Definition of abbreviations: Chr 5 chromosome; CI 5 confidence interval; OR5odds ratio; SNP5single-nucleotide polymorphism; utr5untranslated region.
Figure 1. Estradiol levels and aromatase genotype adjusted for sex
(test for trend, P 5 0.03; n 5 126). Median, interquartile range (box),
and adjacent values (whiskers) are shown. Aromatase genotype distri-
bution: GG (n 5 88), AG (n 5 34), AA (n 5 4).
Roberts, Fallon, Krowka, et al.: Genetic Risk Factors for PPHTN 839
finding supports a role for altered cGMP production in causing
disease in these patients and introduces PDE5A genotype as
a potential pharmacogenomic target.
We also found a relationship between genetic variability in
ANGPT1 and risk of PPHTN. ANGPT1 plays a pivotal role in
angiogenesis, and enhanced ANGPT1 expression or signaling
has been reported to have beneficial effects in several experi-
mental models of PAH (36–38). Although the exact role of
ANGPT1 in pulmonary hypertension remains obscure, our
findings support a role for this molecule in human disease.
Finally, we found an association between PPHTN and genetic
variation in a SNP in S100A4, a member of a family of calcium-
binding proteins involved in regulation of endothelial prolifera-
tion and adhesion (39). S100A4 is expressed in the plexiform
lesions of individuals with certain types of PAH (40). In a murine
model, overexpression of S100A4 results in increased arteriolar
remodeling, plexiform lesions (41), and pulmonary hypertension
in response to hypoxia (42). We have now found a potential
causal link between S100A4 and human disease.
An additional 10 genes had SNPs associated with PPHTN. Six
of these—SERPINE1, RARB (43), caveolin 1 (CAV1) (44),
SMAD3, runt-related transcription factor 1 (RUNX), and
RBPSUH (45)—play a significant role in angiogenesis. SERPINE1
codes for PAI-1, which modulates the proliferative and migra-
tory properties of pulmonary artery smooth muscle cells
(PASMC) and has been shown to be down-regulated in individ-
uals with IPAH (46). We found that genetic variation in NADPH
oxidase 4 (NOX4), xanthine dehydrogenase, and superoxide
dismutase 2 was associated with PPHTN. Redox signaling has
recently been implicated as a potential node of control for
pulmonary vascular response (47). NOX4 localizes to the media
of small pulmonary arteries and, in a hypoxic mouse model,
contributes to PASMC proliferation. Pulmonary arterioles from
IPAH patients demonstrate a significantly increased level of
NOX4 protein, confirming a potentially important role of NOX4
overexpression in PAH (48). Last, genetic variation in NOS2A
may contribute the hypercoagulability and vasoconstriction
characteristic of PPHTN. By the nature of their roles in angio-
genesis, control of coagulation, and vascular tone pathways, these
10 genes offer plausible candidates for determining the risk of
PPHTN.
Disruption in bone morphogenetic protein/transforming
growth factor b signaling has been demonstrated in familial
and idiopathic forms of PAH (49, 50). Although we cannot rule
out the possibility of a rare coding mutation in our subjects, use
of regional linkage disequilibrium and haplotype-tagging SNPs
makes a contribution of common genetic variation in BMPR2,
BMPR1A, ACVRL1, or ENG to portopulmonary hypertension
unlikely.
There are several limitations to this study. First, the sample
size was small, limiting our ability to find genetic alleles associated
with PPHTN that are rare, have small effect sizes, or whose effect
depends on gene–gene or gene–environment interaction. How-
ever, this is one of the largest epidemiologic studies of PPHTN
with very strict case and control phenotypes ever performed and
the first in PAH to use high-throughput genotyping.
A fundamental challenge in high-throughput genetic analyses
is the control of type I error. Given that we analyzed multiple
SNPs for each of more than 90 genes, we can reasonably expect
a certain number of statistically significant associations due to
chance alone. We attempted to minimize the chance of false
positives by using a curated candidate gene list, thus increasing
the prior probability that one or more of these genes has
mechanistic importance in PPHTN. There are commonly used
frequentist methods to adjust for multiple comparisons in high-
throughput studies, such as the Bonferroni correction and false
discovery rate (51). Both methodologies assume that the associ-
ation of each individual SNP with case status is entirely in-
dependent of those of the other SNPs. We have documented
patterns of linkage disequilibrium between genotyped SNPs.
Because most accepted methods to account for multiple compar-
isons do not consider such relatedness, they are overly conser-
vative for this purpose. We have therefore presented the results
without adjustment and consider these results to be hypothesis-
generating. Although replication would be important, the bi-
ologic plausibility of our findings, the multiple gene ‘‘hits’’ in
certain pathways (estrogen signaling and oxidative stress), and
the demonstration of functionality (aromatase genotype and
plasma estradiol levels) are reassuring in terms of the validity
of the findings (52).
Our results implicate common genetic variation in the
pathogenesis of PPHTN. Future studies should focus on repli-
cation in other populations and the mechanisms that explain the
associations between the SNPs of interest and PPHTN.
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